Numerous challenges in tauopathy therapeutics have been identified, including: target selection and prioritization among multiple mechanisms, including tau misfolding, aggregation and spreading; the molecular diversity of pathological tau isoforms [16]; access to tau intracellularly, where toxic species are formed and where critical degenerative events occur; and finally, avoiding chronic interference in physiological roles of tau [34, 66]. The gene discussed is MAPT; the disease is tauopathy.